News

Qiagen and Bayer team up for CDx
Enlarge image

PharmaNetherlandsGermany

Qiagen and Bayer team up for CDx

26.10.2012 - Pharma giant Bayer Healthcare and diagnostics specialist Qiagen N.V.
have forged an alliance in the field of companion diagnostics (CDx).

Initially, the joint efforts will concentrate on several types of solid tumours. But the agreement also lays the groundwork for a strong partnership in creating future companion diagnostics both inside and outside of oncology. The targeted companion diagnostics will be designed to run on Qiagen’s QIAsymphony line of automated instruments. In addition, the partners said that they will collaborate on developing technologies for patient profiling, which may result on research-use-only products for exploratory and translational medicine, said Qiagen.

„As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of Qiagen. Companion diagnostics guide treatment decisions with medications for cancers or other diseases by unlocking molecular information from each patient's tumour genome. „This helps to design more efficient clinical trials and to increase the overall probability of therapeutic success for patients suffering from cancer," said Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare.

Qiagen has more than 15 companion diagnostic collaborations ongoing with pharmaceutical and biotech companies. A major milestone was reached in July, on FDA approval of Therascreen RGQ PCR Kit. The companion diagnostic is used to screen for those metastatic colorectal cancer patients who most likely respond to therapy with Erbitux (cetuximab).

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/qiagen-and-bayer-team-up-for-cdx.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2281.2%
  • TRANSGENE (F)5.08 EUR80.8%
  • TIGENIX (B)1.02 EUR30.8%

FLOP

  • THROMBOGENICS (B)2.90 EUR-42.9%
  • BIONOR PHARMA (N)1.28 NOK-37.6%
  • WILEX (D)2.05 EUR-36.5%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 29.08.2015